-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On September 13, Guangzhou Yinming Biomedical Technology Co.
, Ltd.
(MingMed, hereinafter referred to as "Yinming Bio") announced that the company has completed nearly US$50 million in A+ round of financing
.
In this round of financing, the original investors of Yinming Biotech, Gaorong Capital, Jingcheng Capital, and Huacheng Venture Capital continue to add additional investment, and the new investment of Fangjifeng Capital, Yixian E-commerce, Haisong Capital, Efeng Capital, Taixin Capital, etc.
The company has completed nearly 50 million U.
Public information shows that Yinming was established in October 2019 and is committed to the research and development of "first-in-class" new drugs.
The company's co-founder and CEO (CEO) is Mr.
Zhang Yan
.
In March 2021, the company just announced the completion of a US$60 million Series A financing led by Gaorong Capital
The company's co-founder and chief executive officer (CEO) is Mr.
Regarding this round of financing, Mr.
Zhang Yan, co-founder and CEO (CEO) of Yinming Biotech, introduced: " In the past six months, Yinming Biotech has completed two consecutive rounds of financing, with a cumulative financing amount of nearly 110 million U.
S.
dollars
.
We.
In the past 6 months, Yinming has completed two consecutive rounds of financing, with a cumulative financing amount of nearly US$110 million.
Reference materials:
Reference materials:[1]Yinming has completed nearly US$50 million in Series A+ financing to accelerate clinical trials of blockbuster pipeline drug candidates.
[1]Yinming has completed nearly US$50 million in Series A+ financing to accelerate clinical trials of blockbuster pipeline drug candidates.